The Innovative Medicines Initiative:  Promoting patient involvement      in drug development            Michel Goldman, MD...
Innovative Medicines Initiative:Joining public and private forces                    2 Billion Euro                   1 Bi...
Core objectives • To overcome research bottlenecks in drug   development through collaborative approaches • To increase in...
Key concepts• Non-competitive research for EFPIA companies• Competitive calls for IMI beneficiaries• Open collaboration in...
Major project deliverables   • Patient-reported outcomes   • Predicting biomarkers   • Novel approaches to drug safety   •...
PRO-ACTIVEPatient reported outcomes in chronicobstructive pulmonary disease              Activity Monitoring              ...
U-BIOPRED Towards a new taxonomy of asthmaPaves the way towards tailored treatments forasthmatic patients38 Partners     -...
Clinical Pharmacology & Therapeutics March 2012,http://www.nature.com/doifinder/10.1038/clpt.2011.321
Nature Medicine 18:341,2012
www.imi.europa.eu   THANK YOU !
Upcoming SlideShare
Loading in …5
×

EUPATI launch meeting - Michel Goldman IMI

672 views
616 views

Published on

EUPATI Launch Meeting, 27 March 2012, Copenhagen: Presentation of Michel Goldman, IMI

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
672
On SlideShare
0
From Embeds
0
Number of Embeds
199
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

EUPATI launch meeting - Michel Goldman IMI

  1. 1. The Innovative Medicines Initiative: Promoting patient involvement in drug development Michel Goldman, MD, PhD Executive Director EUPATI Launch, Copenhagen, 27 March 2012
  2. 2. Innovative Medicines Initiative:Joining public and private forces 2 Billion Euro 1 Billion € 1 Billion € Public Private Partnership
  3. 3. Core objectives • To overcome research bottlenecks in drug development through collaborative approaches • To increase investments in the biopharmaceutical sector and provide socio-economic benefits across Europe • To contribute to the health of European citizens
  4. 4. Key concepts• Non-competitive research for EFPIA companies• Competitive calls for IMI beneficiaries• Open collaboration in public-private consortia
  5. 5. Major project deliverables • Patient-reported outcomes • Predicting biomarkers • Novel approaches to drug safety • Innovative tools for translational research
  6. 6. PRO-ACTIVEPatient reported outcomes in chronicobstructive pulmonary disease Activity Monitoring PDA for PROs Physical activity Symptoms reported Time (days)
  7. 7. U-BIOPRED Towards a new taxonomy of asthmaPaves the way towards tailored treatments forasthmatic patients38 Partners - 9 EFPIA companies - 23 Academic institutions - 3 Patients’ organizations - 3 SMEsFirst achievements  A new stepwise algorithm for the stratification of patients with severe asthma Thorax, 66: 910-7 (2011)
  8. 8. Clinical Pharmacology & Therapeutics March 2012,http://www.nature.com/doifinder/10.1038/clpt.2011.321
  9. 9. Nature Medicine 18:341,2012
  10. 10. www.imi.europa.eu THANK YOU !

×